Reviva Pharmaceuticals Q3 2026 net loss narrows 43% to $2.3 million

PUBT · 1d ago
Reviva Pharmaceuticals Q3 2026 net loss narrows 43% to $2.3 million
  • Reviva Pharmaceuticals’ third-quarter 2026 net loss narrowed 43% year over year to $2.3 million.
  • Operating expenses fell 40% year over year to $2.43 million.
  • Cash and cash equivalents rose 21% to $17.46 million at September 30, 2026, from December 31, 2025.
  • FDA feedback on the proposed new brilaroxazine formulation for the RECOVER-2 trial is expected in Q4 2026.
  • RECOVER-2 Phase 3 patient enrollment is targeted for the first half of 2027, subject to additional financing.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Reviva Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611122013PRIMZONEFULLFEED9877013) on November 13, 2026, and is solely responsible for the information contained therein.